Sign in
Taking people in United StatesEarly phase 1

Gut bacteria capsules for adults with hidradenitis suppurativa

Tests oral gut microbiota capsules in adults with hidradenitis suppurativa.

Key facts

Who runs it
University of Minnesota
Where
Minneapolis, United StatesSee the site
Trial code
Registry title
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
Status
Recruiting
Phase
Early phase 1
People taking part
16 people, planned
Started
27 Dec 2023
Expected to end
30 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Fecal Microbiota - lyophilized
  • Placebo drug
Record updated
3 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with hidradenitis suppurativa (HS), a long-term skin disease with painful lumps. It tests capsules of gut bacteria from donor stool against a placebo.

Age
18 years and older
Sex
All sexes can join
Disease stage
HS diagnosed by a dermatologist (skin doctor).
Earlier treatment
All medicines must be at stable doses for 30 days before the start. No antibiotics on the skin or by mouth within 30 days, and no antibiotics by mouth within 90 days, before randomization.

Main reasons for not taking part

  • Pregnancy, breastfeeding or planning a pregnancy during the study
  • Allergy to neomycin or vancomycin, or severe (anaphylactic) food allergies
  • History of inflammatory bowel disease, or large parts of the bowel removed
  • Major bowel surgery within 4 weeks before the start, or major surgery planned during the study
  • Not speaking English, or planning to move within 6 months

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Able and willing to provide informed consent
  • English speaking
  • Age >= 18years of age
  • Diagnosis of hidradenitis suppurativa by a dermatologist
  • Women who are not post-menopausal (at least 12 months of non-therapy induced amenorrhea) or surgically sterile (e.g. absence of ovaries and/or uterus) must remain abstinent or use a highly effective form of birth control (e.g. oral contraception, transdermal patch, barrier, intrauterine device). Periodic abstinence and early withdraw are not acceptable methods
  • Able to comply to study measures in the opinion of the investigator
  • Stable doses of all medications for 30 days prior to baseline

Who cannot take part

  • Extensive bowel resection (e.g., subtotal colectomy, substantial removal of small bowel)
  • No major bowel surgery within 4 weeks prior to baseline or planned major surgery during the study period
  • Allergy to neomycin or vancomycin
  • Anaphylactic food allergies
  • History of inflammatory bowel disease
  • No active skin disease other than HS that could interfere with assessments
  • Non-English speaking
  • Refusal or inability to provide informed consent
  • Planning on moving within 6 months from start of study
  • Pregnancy, breastfeeding or planning pregnancy during study period (negative pregnancy test needed for persons of childbearing potential)
  • Use of any topical or oral antibiotics within 30 days of randomization
  • Use of any oral antibiotics within 90 days of randomization

Where in United States

  • University of MinnesotaMinneapolis, United StatesContact: Thomas PritchardTaking people

About the trial

What the trial wants to find out

HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfortunately, few treatment options are effective. There are currently three FDA-approved treatments for HS, including adalimumab, secukinumab, and bimekizumab, each with only 40- 60% respond to treatment and over 50% lose response within one year . The overarching goal of this pilot study is to investigate the central hypothesis that oral microbiota transplant therapy(MTT) alters the gut microbiome in patients with Hidradenitis Suppurativa (HS), influencing cutaneous microbiota via systemically absorbed gut-derived metabolites.

The 2 groups in the trial

  • MMT groupTreatment being tested

    patients with HS randomized to receive MTT

    Treatment: Fecal Microbiota - lyophilized

  • Placebo groupPlacebo, for comparison

    patients with HS randomized to receive placebo treatment

    Treatment: Placebo drug

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
Plain-language title
Gut bacteria capsules for adults with hidradenitis suppurativaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
3 September 2026